Cannabis Law Report

JUNE 14, 2022

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge. David Nutt and Prof.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 21, 2022

Authority on real estate development and cultivation design, holding a commercial general contractor license since 2002. Founding member of the National Cannabis Industry Association, Lifetime Investor member of the ArcView Group, and sustaining member of Students for Sensible Drug Policy (SSDP) and Americans for Safe Access (ASA).

Research and Development 52

Research and Development Education Advocacy Policy 52

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. Bonini et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MARCH 25, 2019

Both paths are complex processes in which scientific, medical, policy and political forces have influence. There are other avenues Congress can take besides rescheduling marijuana to ameliorate the seeming breakdown in federalism brought about by federal marijuana policy. It was not a policy priority of the Obama administration.

Banking 45

Banking Law Marijuana State Laws 45